83 results on '"Gladman, Dafna D"'
Search Results
2. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
3. The new EULAR/ACR 2019 SLE classification criteria: A predictor of long-term outcomes
4. Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus
5. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
6. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
7. The Incidence and Risk Factors for Venous Thromboembolic Events in Patients with Psoriasis and Psoriatic Arthritis
8. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
9. OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF
10. 25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial
11. Axial involvement in psoriatic arthritis: An update for rheumatologists
12. The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis
13. Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada
14. Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort
15. Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative
16. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
17. Malignancy in psoriatic disease: Results from prospective longitudinal cohorts
18. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
19. 15262 Cardio-metabolic effects of long-term treatment with secukinumab in psoriatic arthritis and ankylosing spondylitis patients: Pooled 3 year analysis
20. Remission in psoriatic arthritis: Definition and predictors
21. Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
22. Mortality in psoriatic arthritis: Risk, causes of death, predictors for death
23. Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI
24. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
25. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
26. A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire
27. How can we define low disease activity in systemic lupus erythematosus?
28. The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis
29. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
30. Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row?
31. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
32. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative
33. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort
34. Epigenetics of psoriatic disease: A systematic review and critical appraisal
35. Should methotrexate remain the first-line drug for psoriasis?
36. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review
37. Dyslipidemia in systemic lupus erythematosus: just another comorbidity?
38. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture
39. Is it time for treat to target in psoriatic arthritis?
40. Clinical Features and Diagnostic Considerations in Psoriatic Arthritis
41. Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus
42. Gene Expression Differences between Psoriasis Patients with and without Inflammatory Arthritis
43. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics
44. Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes
45. The challenge of indication extrapolation for infliximab biosimilars
46. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal
47. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
48. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis
49. Skin Nontuberculous Mycobacterial Infection in Systemic Lupus Erythematosus: An Unusual Skin Infection Mimicking Lupus Vasculitis
50. Comparison of three anti-dsDNA assays: Performance and correlation with systemic lupus erythematosus disease activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.